SLAS 2020 - 9th Annual Conference & Exhibition

January 25–29, 2020
San Diego, CA

Meet Genedata Screener experts at the SLAS 2020 - 9th Annual Conference & Exhibition in San Diego, CA. Ask for a demonstration of Genedata Screener® or Genedata Imagence® at booth #1039.

Don't miss the opportunity to see how Genedata Screener analyzes, visualizes, and manages screening data from in-vitro screening assay technologies across the enterprise, including very complex as well as ultra-high throughput experiments. Its screening-oriented business logic enables rapid processing and comprehensive analysis of complete campaigns.

If you would like to schedule a meeting in advance or receive more information on Genedata Screener, please contact screener@genedata.com.

You also have the chance to find out more about our new solution, Genedata Imagence, a high content screening (HCS) image analysis software based on deep learning. To get more information about Imagence or to arrange a meeting, please contact imagence@genedata.com.

Recommended Oral Presentations

MS-Screening with Genedata: A Fully Automated End-to-End Data analysis Solution for High-Throughput Mass Spectrometry Screening
Isabel Kolinko, Scientific Account Manager, Genedata

Tutorial | Monday, January 27 | 2:00 pm - 2:45 pm | room 10

A new generation of mass spectrometry (MS) instruments is paving the way to faster and more cost-effective drug discovery and lead characterization. By combining label-free, sensitive detection and rich outputs inherent to MS with recently improved sampling, injection and detection methods amenable to high-throughput screening, these instruments—including the RapidFire (Agilent), RapifleX (Bruker), and technologies under development based on accousting droplet ejection coupled to an open port probe sampling interface (Sciex)—can drastically decrease the time and cost required for assay development and screening, while increasing the information obtained per well.
Leveraging the enormous amount of data from high-throughput MS screens requires a software infrastructure suited to the task. This tutorial will show how Genedata solutions cover an entire MS screening workflow from end to end. Using sample datasets, we’ll cover loading of raw spectrogram data coming directly from the MS instrument, automated spectrogram processing and analysis, analysis of the data in a plate-based screening context, quality control of plates and processing of dose response series, and selection of hits. Each step of the workflow can run in a fully automated fashion, maximizing efficiency and scaling to hundreds of plates—in the case of our example, enabling a 7-fold increase in screening speed by removing data analysis bottlenecks. We will also discuss a range of assay setups accommodated by this solution, enabling the productive use of MS for an ever-growing range of screening activities.

 

Streamlined, High-Quality Interpretation of Mechanistic Screening Data
John Uhrig, Scientific Account Manager, Genedata

Tutorial | Tuesday, January 28 | 9:30 am - 10:15 am | room 10

Early inclusion of mechanistic information—and in particular, kinetic information—can dramatically enhance the efficiency and effectiveness of drug programs, by ensuring the propagation of only the most high-quality leads for further development.  This tutorial will showcase Genedata Screener’s enterprise solution for mechanistic analysis, originally developed in close collaboration with major pharma companies. This solution ensures reliable, consistent analysis of mechanistic assays performed with biophysical or tracer-based methods. In an automated and scalable fashion, it readily handles a range of analyses including mechanism of inhibition, progress curves (slow binding/jump dilution), and kinetic probe competition assays (kPCA).
In the tutorial, we’ll highlight a major new achievement of the solution: rapid availability of all mechanistic screening results across the organization, together with a new statistical approach in Screener that assists and automates complex result interpretation and decision-making--even by non-experts--without a compromise in quality or coherence. We illustrate how this software dovetails into a modern pharmaceutical research workflow, delivering reliable result parameters at the speed demanded by today’s drug discovery programs.

 

Launch of HTS at Sygnature Discovery (supported by Titian Software, HighRes Biosolutions and Genedata)
Denise Swift, Senior Scientist, Sygnature Discovery; Toby Winchester, Automation Product Manager, Titian Software; Oliver Leven, Head of Screener Business, Europe, Genedata

Tutorial | Tuesday, January 28 | 9:30 am - 10:15 am | room 11A

This tutorial will discuss how Sygnature Discovery’s new HTS system offers a fully automated platform to deliver high data fidelity with integrated compound tracking. Over the last few years we collaborated with leading industrial vendors to optimally integrate the best in compound management, HTS automation and data analysis. With this new, novel system we can now design and order assay plates in Titian Mosaic SampleBank software, run the fully automated screening process on the HighRes automated system, with data analysis and approval with Genedata Screener. The potential for manual operator errors and process bottlenecks is significantly reduced in this integrated workflow, leading to more robust and higher quality screening. Currently our HTS system is being used to screen Sygnature Discovery’s 150K custom Lead Finder compound library and continues to add to a growing track record of delivering quality novel chemical starting points suitable to start new projects.
In summary HTS has been established at Sygnature in Nottingham, UK, to complement our existing suite of hit finding approaches to offer a more comprehensive integrated hit discovery platform to enable more successful early drug discovery for our clients.

 

Recommended Poster Presentations

[Joint poster with AstraZeneca] A Highly Automated End-to-End Analysis Solution for High-Throughput Mass Spectrometry Screening
Steigele S, Bobby R, Sinclair I, Yee A, Wingfield J, Heyse S

[Joint poster with Janssen] A Highly Scalable Analysis Solution for Transcriptomic Screening
De Wolf H., Verbist B, Florez J, Shatalina M, Laenen G, Adriaensen E, Keersmaekers V, Yee A, Heyse S and Steigele S

[Joint poster with Roche] Completing End-to-End Assay Automation With Automated Data Analysis
Moresis A, Leven O, Kolinko I


[Joint poster with Amgen] Applying Deep Learning for High Content Image Analysis

Links:
www.slas2020.org